These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10639036)

  • 1. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress.
    Konda SD; Aref M; Brechbiel M; Wiener EC
    Invest Radiol; 2000 Jan; 35(1):50-7. PubMed ID: 10639036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts.
    Konda SD; Aref M; Wang S; Brechbiel M; Wiener EC
    MAGMA; 2001 May; 12(2-3):104-13. PubMed ID: 11390265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor.
    Wiener EC; Konda S; Shadron A; Brechbiel M; Gansow O
    Invest Radiol; 1997 Dec; 32(12):748-54. PubMed ID: 9406015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of a 153 Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts.
    Konda SD; Wang S; Brechbiel M; Wiener EC
    Invest Radiol; 2002 Apr; 37(4):199-204. PubMed ID: 11923642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging folate binding protein expression with MRI.
    Wiener EC; Konda SD; Wang S; Brechbiel M
    Acad Radiol; 2002 Aug; 9 Suppl 2():S316-9. PubMed ID: 12188260
    [No Abstract]   [Full Text] [Related]  

  • 6. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
    Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A low molecular weight folate receptor targeted contrast agent for magnetic resonance tumor imaging.
    Kalber TL; Kamaly N; So PW; Pugh JA; Bunch J; McLeod CW; Jorgensen MR; Miller AD; Bell JD
    Mol Imaging Biol; 2011 Aug; 13(4):653-62. PubMed ID: 20809208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement.
    Swanson SD; Kukowska-Latallo JF; Patri AK; Chen C; Ge S; Cao Z; Kotlyar A; East AT; Baker JR
    Int J Nanomedicine; 2008; 3(2):201-10. PubMed ID: 18686779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery.
    Choi H; Choi SR; Zhou R; Kung HF; Chen IW
    Acad Radiol; 2004 Sep; 11(9):996-1004. PubMed ID: 15350580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR imaging of ovarian tumors using folate-receptor-targeted contrast agents.
    Wang ZJ; Boddington S; Wendland M; Meier R; Corot C; Daldrup-Link H
    Pediatr Radiol; 2008 May; 38(5):529-37. PubMed ID: 18357444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced folate-receptor-targeted MR imaging using a Gd-loaded PEG-dendrimer-folate conjugate in a mouse xenograft tumor model.
    Chen WT; Thirumalai D; Shih TT; Chen RC; Tu SY; Lin CI; Yang PC
    Mol Imaging Biol; 2010 Apr; 12(2):145-54. PubMed ID: 19636639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography.
    Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG
    Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting.
    Corot C; Robert P; Lancelot E; Prigent P; Ballet S; Guilbert I; Raynaud JS; Raynal I; Port M
    Magn Reson Med; 2008 Dec; 60(6):1337-46. PubMed ID: 19025883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media.
    Puttagunta NR; Gibby WA; Puttagunta VL
    Invest Radiol; 1996 Oct; 31(10):619-24. PubMed ID: 8889650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of a new MRI contrast agent prepared from polypropyleneimine dendrimers, generation 2.
    Wang SJ; Brechbiel M; Wiener EC
    Invest Radiol; 2003 Oct; 38(10):662-8. PubMed ID: 14501494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligoethylenimine-grafted chitosan as enhanced T1 contrast agent for in vivo targeted tumor MRI.
    Tong X; Liu M; Zhang K; Cao Y; Dong J; Jiang B; Lu B; Zheng H; Zhang H; Pei R
    J Magn Reson Imaging; 2016 Jul; 44(1):23-9. PubMed ID: 26713668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new class of Gd-based DO3A-ethylamine-derived targeted contrast agents for MR and optical imaging.
    Mishra A; Pfeuffer J; Mishra R; Engelmann J; Mishra AK; Ugurbil K; Logothetis NK
    Bioconjug Chem; 2006; 17(3):773-80. PubMed ID: 16704217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.